Company Spotlight

Aphena Pharma Solutions, Inc.

1920 Fisk Road
Cookeville, TN 38506
United States
View Profile

Adare Pharma Solutions

1200 Lenox Drive
Princeton Pike Corporate Center, Suite 100
Lawrence Township, NJ 08648
United States
View Profile

Cytovance Biologics

800 Research Pkwy., Suite 200
Oklahoma City, OK 73104
United States
View Profile


Contract Service Directory


Cimbar Performance Minerals





Company Headquarters

49 Jackson Lake Road
Suite O
Chatsworth, GA 30705
United States

Company Description

Samsung BioLogics is a full service provider of Quality driven cGMP contract manufacturing for the global biopharmaceutical industry. Our facilities are flexibly designed for cost effective production of monoclonal and recombinant drug substance and drug product. Our integrated services include cell line generation, process development, analytical services, clinical and commercial bulk cGMP manufacturing and fill finish services. Our commitment to provide the best Quality Assurance and Quality Control with worldwide regulatory compliance standards ensures dedicated support for our customers. We are centrally located in the heart of Asia, within 20 minutes of Incheon International Airport.

Contract Service Directory

    Related Content

    • Bio News | Breaking News | Collaborations & Alliances | Industry News
      Samsung Biologics Partners with Eli Lilly

      Samsung Biologics Partners with Eli Lilly

      Accelerates the delivery of Covid-19 antibody treatments.
      Contract Pharma Staff 11.20.20

    • Bio News | Biologics, Proteins, Vaccines | Breaking News | Collaborations & Alliances | Industry News
      Samsung Biologics Expands in China

      Samsung Biologics Expands in China

      Partners with Chinese biotech GeneQuantum Healthcare on ADC development.
      Contract Pharma Staff 11.03.20

    • Breaking News | Industry News
      Samsung Biologics, Checkpoint Therapeutics Expand Cosibelimab Mfg. Pact

      Samsung Biologics, Checkpoint Therapeutics Expand Cosibelimab Mfg. Pact

      Samsung Biologics will provide additional commercial-scale drug substance manufacturing.
      Contract Pharma Staff 11.02.20


    • Bio News | Breaking News | Drug Development | Facilities | Industry News
      Samsung Biologics Expands Global Footprint

      Samsung Biologics Expands Global Footprint

      Opens new San Francisco CDO R&D Center.
      10.30.20

    • Biologics, Proteins, Vaccines | Breaking News | Collaborations & Alliances | Drug Development
      Samsung Biologics, Dinona Partner on Potential COVID-19 Antibody Therapy

      Samsung Biologics, Dinona Partner on Potential COVID-19 Antibody Therapy

      Will collaborate for fast-track development of DNP-019, a potential COVID-19 antibody therapy.
      10.20.20

    • Breaking News | R&D
      Samsung Biologics Adopts Solentim Solutions in R&D Center

      Samsung Biologics Adopts Solentim Solutions in R&D Center

      Solentim’s instruments will be used in conjunction with Samsung Biologics’ proprietary cell line platform.
      Contract Pharma Staff 10.07.20


    • Bio News | Biologics, Proteins, Vaccines | Breaking News | Facilities | Industry News | Information Technology | Validation
      Samsung Biologics Achieves ISO27001 Certification

      Samsung Biologics Achieves ISO27001 Certification

      Becomes first CDMO to receive highly touted recognition for information security management.
      11.15.19

    • CPL

      CPL's David Tyler

      CPL's director of business development was on hand at Contract Pharma 2019.
      Contract Pharma

    • Bio News | Breaking News | Industry News | Information Technology
      Goodwin Bio Launches Digitization Initiative

      Goodwin Bio Launches Digitization Initiative

      Invests in a sophisticated electronic quality solution.
      11.11.19


    • Breaking News | Industry News
      Biogen, Samsung Bioepis Enter New Biosimilars Transaction

      Biogen, Samsung Bioepis Enter New Biosimilars Transaction

      Secures exclusive rights to commercialize ophthalmology biosimilars referencing Lucentis and Eylea
      11.07.19

    • Bio News | Biologics, Proteins, Vaccines | Breaking News | cGMP Manufacture | Collaborations & Alliances | Industry News
      Samsung Biologics and Ichnos Sciences Ink Mfg. Deal

      Samsung Biologics and Ichnos Sciences Ink Mfg. Deal

      Samsung to manufacture drug substance for ISB 830 Phase 3 clinical trials and for potential future global commercial supply upon regulatory approval.
      11.05.19

    • Bio News | Breaking News | Facilities | Industry News
      Samsung BioLogics Expands Biomanufacturing Capabilities

      Samsung BioLogics Expands Biomanufacturing Capabilities

      Implements large scale N-1 perfusion for commercial application
      08.12.19


    • Bio News | Breaking News | Industry News | Promotions & Moves | QA/QC | Regulatory Affairs
      Goodwin Biotechnology Bolsters Quality & Regulatory Capabilities

      Goodwin Biotechnology Bolsters Quality & Regulatory Capabilities

      Names Gerald Orehostky as vice president of quality and regulatory operations
      08.07.19

    • Bio News | Breaking News | cGMP Manufacture | Collaborations & Alliances | Industry News
      Samsung BioLogics and UCB Sign Third Drug Manufacturing Deal

      Samsung BioLogics and UCB Sign Third Drug Manufacturing Deal

      The CDMO will also produce UCB's anti-tau candidate to treat progressive supranuclear palsy
      07.31.19

    • 21	Biogen

      21 Biogen

      ...
      07.15.19

    • Promotions & Moves
      Pii Appoints Business Executives

      Pii Appoints Business Executives

      Ideus, Grellner and McFarlane to head market engagement and business management activities
      07.02.19